○ Human lifespan evidence: none (animal/preclinical or mechanism only)

Two caveats govern every page on this site. (1) Telomere length is a contested aging biomarker — it is measured differently by different methods, varies between tissues, and "longer" is not straightforwardly "healthier"; changing a telomere-length or telomerase-activity number in a trial is not the same as slowing human aging. (2) Activating telomerase is not risk-free — telomerase is silenced in most somatic cells and reactivated in most cancers, so its activation raises an unresolved cancer-risk question. Tellingly, the only FDA-approved telomerase drug — imetelstat (RYTELO, 2024) — inhibits telomerase to treat cancer (lower-risk MDS), the opposite direction from the anti-aging "activation" narrative.

What it is

Class: Botanical parent compound (thin standalone data)

Also known as: Astragalus membranaceus, cycloastragenol, astragaloside IV

Relationship to telomere biology: Astragalus membranaceus and its purified saponin cycloastragenol are the botanical parent material from which TA-65 is derived. Cycloastragenol is the compound with reported telomerase-activating activity, but standalone human telomere data on raw astragalus/cycloastragenol (outside the branded TA-65 formulation) are thin.

Regulatory status

Sold as a botanical dietary supplement; not an approved drug and not approved for any anti-aging indication. Human telomere evidence outside the TA-65 formulation is limited to preclinical and marketing-level claims.

Mechanism

Cycloastragenol is the putative active telomerase activator in astragalus; most of the human evidence is really the TA-65 program (see the TA-65 page). Raw-compound human telomere data are thin. See /telomerase-tert-terc.

Evidence — Preclinical / thin human

Species / population	Cell and animal studies of cycloastragenol; human telomere data are essentially the branded TA-65 trials rather than raw astragalus.
Exposure, route, schedule	Cycloastragenol / astragalus extracts (variable, non-standardised outside TA-65).
Comparator / duration	Mostly preclinical; no standalone powered human telomere RCT of the raw compound.
Endpoint / numeric result	In-vitro telomerase activation and preclinical signals; standalone human telomere-length outcomes are not established outside TA-65.
What it did NOT establish	No qualifying standalone human RCT for a telomere or aging outcome; no lifespan evidence. The activation-cancer-risk question applies.

Negative or null findings

Human telomere evidence for raw astragalus/cycloastragenol is thin and largely subsumed by the commercial TA-65 program.
No lifespan or clinical-outcome data; telomerase activation carries an unresolved cancer-risk question.

Related mechanisms

telomerase-tert-terc